2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchMeSH KeywordsCognitive Behavioral TherapyDepressionDepressive Disorder, MajorHumansRandomized Controlled Trials as TopicSuicidal IdeationConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indicationsKetamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesLong-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDouble-Blind MethodHumansNasal SpraysQuality of LifeTreatment OutcomeConceptsTreatment-resistant depressionEsketamine treatmentMontgomery-Åsberg Depression Rating Scale (MADRS) total scoreCommon treatment-emergent adverse eventsLong-term extension studyTreatment-emergent adverse eventsEsketamine nasal sprayMean cumulative durationLong-term tolerabilityNew safety signalsHealth-related qualityMaintenance of responseLong-term treatmentMajor depressive disorderLong-term safetyPhase 3Scale total scoreMaintenance phaseOral antidepressantsData cutoffAdverse eventsMaintenance treatmentSustained efficacyEligible participantsDepression ratingsPredictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Turkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDouble-Blind MethodHumansNasal SpraysTreatment OutcomeConceptsTreatment-resistant depressionEsketamine nasal sprayNasal sprayDay 28Day 8Clinical Global Impression-Severity scoreCGI-S scoresCurrent depressive episodePredictors of responsePlacebo nasal sprayIdentification of predictorsOral antidepressantsBaseline patientAcute trialPooled analysisDepressive episodeRemissionPsychiatric characteristicsPatientsSignificant anxietyYounger ageTreatment assignmentPotential predictorsPhase 3Predictors
2022
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorElectroconvulsive TherapyHumansKetamineRandomized Controlled Trials as TopicSuicide, AttemptedConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profile
2021
Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent.
Voelker J, Cai Q, Kuvadia H, Daly E, Connolly N, Pesa J, Sheehan J, Wilkinson S. Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent. The Journal Of Clinical Psychiatry 2021, 82 PMID: 34529898, DOI: 10.4088/jcp.20m13842.Peer-Reviewed Original ResearchConceptsMajor depressive episodeMental health servicesHealth care resource utilizationHealth servicesSuicidal ideationDepressive episodeMental health treatmentLogistic regression modelsPrescription medicationsOutpatient careInpatient careHigher oddsExtensive burdenHealth treatmentUnmet needDrug useCohortCareAdult participantsNational surveyIdeationRegression modelsGreatest barrierTreatmentEpisodes
2018
Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans
Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatric Services 2018, 69: 542-548. PMID: 29385954, PMCID: PMC6248332, DOI: 10.1176/appi.ps.201700364.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBipolar DisorderDatabases, FactualDepressive Disorder, MajorElectroconvulsive TherapyFemaleHumansInsurance, HealthMaleMiddle AgedMultimorbidityUnited StatesYoung AdultConceptsElectroconvulsive therapyMood disordersClinical characteristicsECT useUse of ECTCharacteristics of patientsProportion of patientsComorbid psychiatric disordersMajor depressive disorderNumber of prescriptionsSubstance use disordersOutpatient psychotherapy visitsECT patientsECT utilization rateMarketScan databasePsychotherapy visitsPsychotropic medicationsDepressive disorderPsychiatric disordersService useUse disordersPatientsECT utilizationBipolar disorderCommercial insurance
2017
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughtsCognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy And Psychosomatics 2017, 86: 162-167. PMID: 28490030, PMCID: PMC5516265, DOI: 10.1159/000457960.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdultAntidepressive AgentsCognitionCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantFemaleHumansKaplan-Meier EstimateKetamineMaleMiddle AgedPsychiatric Status Rating ScalesRecurrenceRemission InductionTreatment OutcomeYoung AdultConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsKetamine's antidepressant effectsKetamine exposureIntravenous ketamineKetamine infusion therapyWeeks of protocolOpen-label trialLong-term treatmentStandardized clinical protocolCognitive behavior therapyKetamine nonrespondersKetamine respondersRelapse rateMedian timeInfusion therapyClinical protocolsKetamineNeurobiological changesRemissionBehavioral therapyTherapyWeeksBehavior therapyComputer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy
Wilkinson ST, Ostroff RB, Sanacora G. Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. Journal Of Ect 2017, 33: 52-57. PMID: 27564424, PMCID: PMC5315599, DOI: 10.1097/yct.0000000000000348.Peer-Reviewed Original ResearchConceptsComputer-assisted cognitive-behavior therapyElectroconvulsive therapyCognitive behavior therapyMean timeOpen-label trialMajor depressive episodeMean numberBehavior therapyAcute treatmentDepressive episodeIndex coursePrevent relapseDepression severityRelapsePotential efficacyTherapyMonthsOwn homesPreliminary evidenceRemittersTrialsSubjectsEntire sampleHoursRemission